Scholars@Duke publication: A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)

A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548

Publication , Conference

Weller, M; Vlahovic, G; Khasraw, M; Brandes, AA; Zwirtes, R; Tatsuoka, K; Carpentier, AF; Reardon, DA; Bent, M

Published in: Annals of Oncology

October 1, 2016

Published version (DOI)

Duke Scholars

Author Gordana Vlahovic Medicine, Medical Oncology

Author Mustafa Khasraw Neurosurgery

Published In

Annals of Oncology

DOI

10.1093/annonc/mdw367.34

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

Start / End Page

vi113

Related Subject Headings

Oncology & Carcinogenesis
3211 Oncology and carcinogenesis
3202 Clinical sciences
1112 Oncology and Carcinogenesis

Citation

APA

Chicago

ICMJE

MLA

NLM

Weller, M., Vlahovic, G., Khasraw, M., Brandes, A. A., Zwirtes, R., Tatsuoka, K., … Bent, M. (2016). A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548. In Annals of Oncology (Vol. 27, p. vi113). https://doi.org/10.1093/annonc/mdw367.34

Weller, M., G. Vlahovic, M. Khasraw, A. A. Brandes, R. Zwirtes, K. Tatsuoka, A. F. Carpentier, D. A. Reardon, and M. Bent. “A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548.” In Annals of Oncology, 27:vi113, 2016. https://doi.org/10.1093/annonc/mdw367.34.

Weller M, Vlahovic G, Khasraw M, Brandes AA, Zwirtes R, Tatsuoka K, et al. A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548. In: Annals of Oncology. 2016. p. vi113.

Weller, M., et al. “A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548.” Annals of Oncology, vol. 27, 2016, p. vi113. Scopus, doi:10.1093/annonc/mdw367.34.

Weller M, Vlahovic G, Khasraw M, Brandes AA, Zwirtes R, Tatsuoka K, Carpentier AF, Reardon DA, Bent M. A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548. Annals of Oncology. 2016. p. vi113.

Published In

Annals of Oncology

DOI

10.1093/annonc/mdw367.34

EISSN

1569-8041

ISSN

0923-7534

Publication Date

October 1, 2016

Volume

Start / End Page

vi113

Related Subject Headings

Oncology & Carcinogenesis
3211 Oncology and carcinogenesis
3202 Clinical sciences
1112 Oncology and Carcinogenesis